1.. Introduction {#S6}
================

Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental pollutants formed from incomplete combustion of organic matter ([@R47]). People can be potentially exposed to PAHs from numerous sources including fuels such as oil, gas, coal, wood ([@R18]; [@R9]; [@R37]; [@R3]; [@R33]; [@R39]), diet ([@R38]), and smoking cigarettes ([@R26]; [@R31]; [@R43]; [@R52]). Some PAHs induce tumors in animals and are carcinogenic to humans ([@R1]; [@R21]). For example, benzo\[*a*\]pyrene induces malignant lesions in animal studies ([@R20]). Urinary concentrations of PAH metabolites, specifically monohydroxylated PAHs (OH-PAHs), have been used as biomarkers of human exposure to PAHs including naphthalene, fluorene, phenanthrene and pyrene ([@R26]; [@R24]; [@R25]).

Smoking is the leading cause of preventable disease, disability, and death in the United States ([@R7]; [@R10]). In 2009, the U.S. Food and Drug Administration (FDA) obtained authority through the Family Smoking Prevention and Tobacco Control Act ([@R13]) to regulate manufacturing, marketing and distribution of tobacco products to protect public health. To help monitor the impact of these regulatory actions, FDA partnered with the National Institute on Drug Abuse at the National Institutes of Health to launch the Population Assessment of Tobacco and Health (PATH) Study ([@R19]) to evaluate the impact of tobacco use on public health.

In the United States, general population exposures to PAHs have been assessed through the National Health and Nutrition Examination Survey (NHANES) since the early 2000s ([@R26]; [@R6]), and these data have been used in addressing various health risks ([@R40]; [@R29]; [@R11]; [@R22]). However, assessment of exposure to PAHs among tobacco product users in NHANES is limited to cigarette smokers ([@R44]). Information on the extent of PAHs exposure among users of non-combustible tobacco products (e.g., e-cigarettes, smokeless tobacco products) is limited to relatively small studies ([@R12]; [@R15]; [@R41]), even though use of these products may be on the rise, particularly among adolescents and young adults ([@R8]).

To address these gaps, we used PATH Study Wave 1 data to evaluate exposure to PAHs among never users and tobacco product users, including users of combustible and non-combustible tobacco products. We report reference ranges of seven OH-PAH urinary biomarkers: 1hydroxynaphthalene, 2-hydroxynaphthalene, 2-hydroxyfluorene, 3-hydroxyfluorene, 1-hydroxyphenanthrene, the sum of 2-hydroxyphenanthrene and 3-hydroxyphenanthrene (Σ2,3-hydroxyphenanthrene), and 1-hydroxypyrene by tobacco product user groups.

2.. Materials and methods {#S7}
=========================

2.1.. Study design and participants {#S8}
-----------------------------------

Data used in this current analysis are from Wave 1 of the PATH Study, collected from September 12, 2013 to December 15, 2014. Recruitment employed address-based, area-probability sampling, using an in-person household screener to select youth (ages 12--17) and adults. Adult tobacco users, young adults ages 18 to 24, and African Americans were oversampled relative to population proportions. A stratified probability sample of 11,522 adults who completed the Wave 1 adult interview and provided a spot urine for the planned analyses was selected for biomarker analysis from a diverse mix of tobacco product user groups. Estimates for this group of adults can be described as representative of never, current, and recent former (within 12 months) users of tobacco products in the U.S. civilian, noninstitutionalized adult population at the time of Wave 1. Specific details of the PATH study design, participant recruitment, and collection and handling of biological specimens have been presented previously ([@R19]). The study was conducted by Westat and approved by the Westat Institutional Review Board. For this study, we present results for 11,519 samples which had quantifiable levels of OH-PAHs.

2.2.. Quantitation of PAH biomakers in urine {#S9}
--------------------------------------------

The PATH Study measured urinary concentrations of seven OHPAHs using enzymatic hydrolysis, online solid phase extraction, and high performance liquid chromatography isotope dilution tandem mass spectrometry (online SPE-HPLC-MS/MS) as previously described ([@R49]). In brief, sulfate and glucuronide conjugates of OH-PAHs were enzymatically hydrolyzed from 100 μL urine, followed by online solid phase extraction and quantification by LC-MS/MS with ^13^C isotope--labeled internal standards. The inter- and intra-day precision of the method varied from 5.2 to 16.7%, depending on the analyte and concentration. The limits of detection (LOD) were 0.06 μg/L (1-hydroxynaphthalene), 0.09 μg/L (2-hydroxynaphthalene), 0.008 μg/L (2-hydroxyfluorene, 3-hydroxyfluorene), 0.009 μg/L (1-hydroxyphenanthrene), 0.01 μg/L (Σ2,3-hydroxyphenanthrene), and 0.07 μg/L (1-hydroxypyrene). The analytical measurements followed strict quality control/quality assurance protocols, including participation in quality assessment schemes to demonstrate the method accuracy and precision. Furthermore, along with study samples, each analytical run included spiked quality control materials and reagent blanks to assure the accuracy and reliability of the data. Details of the analytical procedure used are available at <https://wwwn.cdc.gov/nchs/data/nhanes/2013-2014/labmethods/PAH_H_MET_Aromatic_Hydrocarbons.pdf>[.](https://wwwn.cdc.gov/nchs/data/nhanes/2013-2014/labmethods/PAH_H_MET_Aromatic_Hydrocarbons.pdf)

2.3.. Tobacco product user groups and specific product user groups {#S10}
------------------------------------------------------------------

Participants completed the Wave 1 Adult Interview and provided detailed information about the tobacco product use. This information was used to determine whether they were current established users (see definitions in [Table 1](#T1){ref-type="table"} ([@R19])) of a combustible product (i.e., cigarette, traditional cigar, cigarillo, filtered cigar, hookah, pipe) or a non-combustible product (i.e., e-cigarette, smokeless tobacco, snus pouches, dissolvable tobacco). In addition, participants reported frequency (i.e., some days, everyday) and last time of tobacco product use. Self-reported and biomarker data are known to be highly correlated ([@R50]). Furthermore, previous research suggest the validity of self-reported data among PATH participants ([@R48]).

Based on participants' self-report, we categorized participants into three main tobacco user groups ([Table 1a](#T1){ref-type="table"}: Tobacco user group): never-tobacco user (never user; n = 1700), exclusive current established combustible products user (combustible products user; n = 5767) and exclusive current established non-combustible products user (noncombustible products user; n = 860). We categorized participants who reported being both combustible products user and non-combustible products user as dual-group user (n = 1258), and participants not included in the above user groups (including former smokers/users) as other user (n = 1934). We provided only descriptive statistical data for dual-group user and other user in the total population estimates in the [Supplemental material](#SD1){ref-type="supplementary-material"}. Participants who used more than one product were considered exclusive current established users if all products were in the same group (combustible or non-combustible).

We further defined four specific product user groups ([Table 1b](#T1){ref-type="table"}: Specific product user groups): exclusive current established cigarette user (cigarette user), exclusive current established smokeless product user (SLT user), exclusive current established e-cigarette user (e-cigarette user), and never user as one specific product reference user group.

2.4.. Statistical evaluation {#S11}
----------------------------

We used SAS (version 9.4; SAS Institute Inc., Cary, NC) and SUDAAN (version 11; Research Triangle Institute, Research Triangle Park, NC) for all statistical analyses. SAS and SUDAAN incorporate the appropriate sample weights to account for the complex design of the PATH Study. Further information on the weighting procedure can be obtained from the PATH Study Biomarker Restricted Use File User Guide (available at <https://doi.org/10.3886/ICPSR36840.v1>[)](https://doi.org/10.3886/ICPSR36840.v1). The variance estimate was a balanced repeated replication with Fay's method (Fay = 0.3), and statistical significance was set at *p* \< 0.05. The Bonferroni adjustment was used for multiple testing, and the *p*values were multiplied by the number of comparisons in the descriptive analyses whereas the alphas for the adjusted model based confidence interval (CI) were divided by the number of comparisons. Data were weighted and all estimates produced are representative of never users, recent former users, and current users of tobacco products in the civilian, non-institutionalized U.S. population at the time of PATH Study Wave 1.

We defined four major racial/ethnic groups based on self-reported data: non-Hispanic white, non-Hispanic black, Hispanic, and Asian and Other (which included multiracial). We stratified age, reported in years at the last birthday, into four groups: 18--24 years, 25--34 years, 35--54 years, and 55 years and older.

We calculated the weighted frequency of detection for each biomarker. We also calculated the geometric mean (GM) and distribution percentiles for both the volume-based (in μg/L for 1-hydroxynaphthalene and 2-hydroxynaphthalene, and ng/L for the remaining biomarkers), and creatinine-corrected (in μg/g creatinine for 1-hydroxynaphthalene and 2-hydroxynaphthalene, and ng/g creatinine for the other biomarkers; see [Supplemental tables](#SD1){ref-type="supplementary-material"}) concentrations by tobacco product user group, age, sex, and race/ethnicity group. For concentrations below the LOD, as recommended for the analysis of NHANES data we used a value equal to the LOD divided by the square root of 2 ([@R17]). We only calculated creatinine corrected concentrations in the descriptive analyses and included the log~10~ transformed creatinine as a covariate in the regression model for the 11,266 samples (weighted percentage, 98.5%) with normal (10--370 mg/dL) creatinine levels ([@R4]).

For each biomarker, we conducted weighted univariate analysis using one way ANOVA to compare GMs for the three main user groups: combustible products user, non-combustible products user, and never user. Due to skewed distributions, we used log~10~ transformed OH-PAH concentrations as the dependent variable. Of note, although the log~10~ tranformed biomarker distribution was not perfectly normal, the absolute values of skewness and kurtosis for each log~10~ transformed biomarker concentrations were between 0.025 and 0.5, and 0.25--1.4, respectively, all within the normal distribution range. The three-level user group was the independent variable. We also performed another analysis by adding the log~10~ transformed creatinine as a covariate to adjust for urinary dilution ([@R2]).

We also used weighted ANCOVA to evaluate the log~10~ transformed OH-PAH concentrations and their relationship with the three-level to-bacco main user groups adjusting by log~10~(creatinine), race/ethnicity, sex, and age, by calculating the covariate-adjusted GM ratios where never user was the reference group. The higher GM ratio, the more significant is the difference between the GMs in a given specific tobacco user group compared to the reference never user group. This approach allowed both the urinary biomarker concentration to be appropriately adjusted for urinary creatinine and the statistical significance of other variables in the model to be independent of effects of creatinine concentration.

Similarly, we also calculated GMs for the four-level specific product user groups (cigarette user, e-cigarette user, SLT user, and never user). We conducted the weighted univariate one way ANOVA and multiple regression ANCOVA analyses of the log transformed OH-PAH concentration by these four-level user groups, adjusted by log~10~(creatinine), race/ethnicity, sex, and age. We also stratified the analyses based on frequency of product use (everyday or some days) and by the last time the product was used (within the last hour, within the past three days, more than three days ago).

3.. Results {#S12}
===========

3.1.. Biomarkers of exposure by tobacco user groups {#S13}
---------------------------------------------------

We report data for seven urinary OH-PAH metabolites from 11,519 (unweighted) participants in Wave 1 of the PATH Study. The percentage of missing data ranged from 0% to 0.24%, depending on the biomarker. Weighted detection frequencies for six of the seven OH-PAH were \> 99%; the weighted detection frequency was lowest for 1-hydroxypyrene (89.6%; [Supplemental Table 1S--A](#SD1){ref-type="supplementary-material"}). For our primary analysis, the number of participants were 1700 (never user), 5767 (combustible products user), and 860 (non-combustible products user), and their demographic characteristics are shown in [Supplemental Table 1SB](#SD1){ref-type="supplementary-material"}. For each tobacco user group, we calculated GMs and 95% CIs of the seven biomarkers ([Fig. 1](#F1){ref-type="fig"}, [Supplemental Table 2S](#SD1){ref-type="supplementary-material"}). GMs and selected percentiles by demographic categories and all tobacco user groups (both creatinine uncorrected and corrected) are provided in [Supplemental Table 3S-A and 3S-B](#SD1){ref-type="supplementary-material"}. For all biomarkers, combustible products users had significantly higher GMs than non-combustible products users and never users ([Fig. 1](#F1){ref-type="fig"}, [Supplemental Table 2S and Table 4S](#SD1){ref-type="supplementary-material"}). On the other hand, non-combustible products users had significantly higher GMs than never users for most biomarkers ([Fig. 1](#F1){ref-type="fig"}, [Supplemental Table 2S and Table 4S](#SD1){ref-type="supplementary-material"}), with the exception of 1-hydroxynaphthalene (*p* = 1.00), 2-hydroxynaphthalene (*p* = 1.00) and 1-hydroxyphenanthrene (*p* = 0.14). The ANOVA comparison by user groups after adjusting by log~10~ creatinine did not alter the results (data not shown). Similarly, although use of the Bonferroni method for multiple testing may increase type II error, it did not seem to appreciably affect the results of the comparisons (data not shown).

From the ANCOVA model results ([Fig. 1](#F1){ref-type="fig"}, [Supplemental Table 5S](#SD1){ref-type="supplementary-material"}), compared to never users, the adjusted GM ratio (95% CI) for combustible products users was highest for 3-hydroxyfluorene (7.40 (6.80--8.05)), followed by 1-hydroxynaphthalene (6.76 (6.03--7.58)), and 2-hydroxyfluorene (5.20 (4.81--5.62)); for 1-hydroxypyrene, one of the most frequently used PAH exposure biomarkers, the adjusted GM ratio was 2.28 (2.11--2.46). For non-combustible products users, all adjusted GM ratios were much smaller than the ratios between combustible products users and never users. 3-Hydroxyfluorene and 2-hydroxyfluorene had the highest ratios \[1.90 (1.69--2.14) and 1.62 (1.45--1.82), respectively\]. For 1-hydroxynaphthalene, the relative standard error (RSE) was 52.45%, exceeding the 30% value above which estimates are considered unreliable ([@R5]).

3.2.. Biomarkers of exposure by specific type of tobacco product {#S14}
----------------------------------------------------------------

[Fig. 1](#F1){ref-type="fig"} also presents GMs (95% CI) of the seven OH-PAHs by specific tobacco-product user groups: cigarette user, SLT user, e-cigarette user, and never user. For all biomarkers examined, cigarette user had GMs significantly higher than any of the other three specific tobacco-product user groups ([Fig. 1](#F1){ref-type="fig"}, [Supplemental Tables 2S and 4S](#SD1){ref-type="supplementary-material"}). Compared to ecigarette user, SLT user had significantly higher GMs of 2-hydroxyfluorene, 3-hydroxyfluorene, and Σ2,3-hydroxyphenanthrene. Furthermore, SLT user, compared to never user, had significantly higher GMs of four biomarkers (2-hydroxyfluorene, 3-hydroxyfluorene, Σ2,3-hydroxyphenanthrene, 1-hydroxypyrene). Last, e-cigarette user had significantly higher GMs than never user for 3-hydroxyfluorene and 1hydroxypyrene.

In adjusted ANCOVA model analysis ([Fig. 1](#F1){ref-type="fig"}, [Supplemental Table 5S](#SD1){ref-type="supplementary-material"}), compared to never user, cigarette user had adjusted GM ratios (95% CI) (e.g., 5.77 (5.27--6.31) and 8.10 (7.63--9.24) for 2-hydroxyfluorene and 3-hydroxyfluorene, respectively) significantly higher than SLT user (e.g., 1.83 (1.57--2.13) for 2-hydroxyfluorene and 2.29 (1.95--2.69) for 3-hydroxyfluorene) or e-cigarette user (e.g., 1.35 (1.13--1.61) for 2-hydroxyfluorene and 1.38 (1.15--1.66) for 3-hydroxyfluorene) regardless of biomarker; the RSE were also lowest among cigarette user for all biomarkers. In contrast, compared to never user, the adjusted GM ratios for SLT user or e-cigarette user were relatively small and with relatively high RSE. Of note, the relatively small sample size (\< 50) for e-cigarette and SLT user may have contributed to a few estimates having relatively large RSE. Also, the large RSE for the GM ratio may relate, at least in part, to the fact that the GM ratio was close to one, which resulted in a rather small denominator for the RSE on the log scale, and hence large RSE. Large RSEs should be interpreted with caution.

3.3.. Biomarkers of exposure by frequency of tobacco product use {#S15}
----------------------------------------------------------------

We further analyzed OH-PAH concentrations among cigarette user and other users according to smoking frequency (everyday vs some days) and last time used ([Table 2](#T2){ref-type="table"}, [Supplemental 6S](#SD1){ref-type="supplementary-material"}). Cigarette user's GM concentrations of all biomarkers were significantly higher in everyday user than in some day user. In addition, GMs of all OH-PAH biomarkers were highest in cigarette user who smoked in the last hour, followed by those who last smoked within 3 days, and those who last smoked \> 3 days ago. However, the GMs of 1-hydroxyphenanthrene in cigarette user who last smoked within 3 days or \> 3 days ago did not differ significantly (*p =* 0.51).

Everyday SLT user had significantly higher GMs than some days SLT user for all biomarkers with the exception of 1-hydroxynaphthalene (*p =* 0.86) and 2-hydroxynaphthalene (*p* = 0.14). In addition, SLT user who used the product in the last hour had significantly higher GMs of most OH-PAH biomarkers (except for 1-hydroxynaphthalene and 2hydroxynaphthalene) than those who had used the product within 3 days. SLT user who had used the product in the last hour had significantly higher GM for 3-hydroxyfluorene (*p =* 0.047) than those who had last used over three days previously. We observed no significant differences in GMs for all biomarkers for SLT user who used the product within 3 days or \> 3 days.

Of note, we observed no significant differences in GM of most biomarkers ([Table 2](#T2){ref-type="table"}) in everyday and some days e-cigarette users. We also observed no statistically significant differences regardless of the last time the product was used.

4.. Discussion {#S16}
==============

The PATH Study quantified seven OH-PAHs in 11,519 (unweighted) urine samples collected from a tobacco product user sample of persons 18 years of age and older who participated in Wave 1 of the PATH Study between 2013 and 2014, with the corresponding sampling weight representing the U.S. population. The PATH Study analysis detected six OH-PAH biomarkers in over 99% of the sample who provided biospecimens, confirming widespread exposure to naphthalene, fluorene, phenanthrene, and pyrene in the general U.S. adult population, consistent with data from NHANES ([@R6]).

To increase our understanding of the contribution of tobacco product use and exposure to PAHs, we investigated urinary concentrations of monohydroxylated PAH biomarkers in three mutually exclusive tobacco user groups: combustible products user, non-combustible products user, and never user. First, the OH-PAH biomarker concentrations and concentration ranges among combustible products user and never user were consistent with those reported for a subsample of adult smokers and non-smokers, respectively, in NHANES 2011--2012 ([@R6]). More importantly, as expected, because PAHs form during incomplete combustion, combustible products users had significantly higher GM concentrations of all OH-PAH biomarkers evaluated than non-combustible products users or never users. However, although noncombustible products users had significantly higher GM concentrations of the biomarkers of fluorene, phenanthrene, and pyrene compared to never users, GMs of the two naphthalene biomarkers between these two user groups, did not differ significantly.

We used adjusted GM ratios as suggestive indicators of the selectivity of the biomarkers to assess PAH exposure associated with tobacco use. 2-Hydroxyfluorene and 3-hydroxyfluorene, which correlated well with each other as expected for two metabolites of the same parent compound, fluorene ([@R26]), were two of the three biomarkers with the highest adjusted GM ratios both among combustible products user and non-combustible products user. 1-Hydroxynaphthalene also had relatively high GM ratios, particularly for combustible products user, but the RSE was larger than for the fluorene biomarkers. Of note, 1-hydroxynaphthalene, a non-specific metabolite of naphthalene, is also a known metabolite of carbaryl (1-naphthyl-*N*-methylcarbamate), a major active pesticide ingredient ([@R30]; [@R32]). Recent exposure to carbaryl may contribute, at least in part, to the concentrations of 1-hydroxynaphthalene detected among PATH Study participants ([@R30]; [@R32]). We believe that the lack of specificity of 1-hydroxynaphthalalene diminishes its suitability as a biomarker of naphthalene exposure from tobacco-use only. 1-Hydroxypyrene, a commonly used OH-PAH biomarker ([@R25]; [@R42]; [@R51]; [@R23]) also had higher GM ratios in combustible products users than in non-combustible products users, but the RSE, particularly among non-combustible products users, was considerably larger than for the two fluorene biomarkers. Taken together, these results suggest that 2-hydroxyfluorene, 3-hydroxyfluorene, and, to some extent, 1-hydroxypyrene might be sensitive and specific biomarkers for the purposes of assessing exposure to PAHs from use of tobacco products, particularly combustible products.

Because PAHs form during combustion and use of non-combustible products does not involve combustion, the much lower GMs and adjusted GM ratios (vs never user) of OH-PAH biomarkers among noncombustible products user (including e-cigarette user and SLT user) relative to combustible products user were expected.

GMs of 2-hydroxyfluorene, 3-hydroxyfluorene, Σ2,3-hydroxyphenanthrene, and 1-hydroxypyrene were significantly higher for SLT users compared to never users. Smokeless tobacco products can contain PAHs ([@R31]; [@R16]; [@R45]; [@R46]; [@R14]), which could explain the above differences in biomarkers concentrations between exclusive users of smokeless tobacco and never users. GMs of 3-hydroxyfluorene and 1-hydroxypyrene were also significantly higher among e-cigarette users than never users. However, because PAHs have not been consistently detected in e-cigarette aerosols ([@R35]; [@R34]; [@R28]; [@R36]), PAH metabolites in e-cigarette users may relate to other activities (e.g., diet ([@R38])) instead of use of tobacco products.

For specific product user groups, we evaluated the OH-PAH biomarkers concentrations based on frequency of product use and by the last time used. Cigarette users who smoked everyday had significantly higher GMs of all biomarkers than cigarette users who did not smoke as often, and cigarette users who smoked most recently had the highest GMs. These data are consistent with the relatively short half-life (2.5--6.1 h) of PAHs in humans ([@R27]) and their rapid urinary excretion. SLT users who used the product everyday also had significantly higher GMs for most biomarkers (except 1-hydroxynaphthalene and 2-hydroxynaphthalene) than occasional users; persons who used the product within the last hour also had the highest concentrations of these biomarkers. The much lower concentrations of OH-PAHs among e-cigarette users and the non-persistent nature of the biomarkers likely explain the lack of apparent frequency-related concentration trend for these biomarkers in this group of users.

5.. Conclusions {#S17}
===============

In summary, we present the first representative PAHs exposure data in never and select (including current) users of both combustible and non-combustible tobacco products in the U.S. adult general population between 2013 and 2014. The almost universal detection of six of the seven OH-PAH biomarkers evaluated and the similar GM concentrations of all seven biomarkers to those reported before among adults participating in NHANES 2011--2012 confirm the widespread exposure of the U.S. population to PAHs. Users of combustible tobacco products had significantly higher concentrations of all OH-PAHs than users of non-combustible tobacco products and never users; concentrations of some PAH biomarkers were significantly higher in users of smokeless tobacco products and e-cigarettes than in never users. The reported OHPAH concentration differences by type and frequency of tobacco product use highlight the importance of evaluating the potential health impact from PAH exposure from the use of these products. Lastly, the PATH Study Wave 1 data can establish a baseline to identify PAH exposure trends as tobacco use behavior may change over time.
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![Geometric mean (GM) biomarker concentrations (95% CI)^a^ and adjusted geometric mean ratios (95% CI) from ANCOVA model (never user as reference)^b,c^ by tobacco user groups^d^ and specific tobacco-product user groups^e^, PATH Study Wave 1 (2013--2014).\
^a^GM concentration in μg/L for 1-hydroxynaphthalene and 2-hydroxynaphthalene; in ng/L for the rest of the biomarkers; error bars display the 95% confidence intervals.\
^b^Adjusted for log~10~(creatinine), race/ethnicity, sex, and age.\
^c^Relative standard error (RSE) \> 30% ([@R5]).\
^d^Three main tobacco user groups: never user (never), non-combustible products user (n-combust), and combustible products user (combust) are mutually exclusive.\
^e^Four specific tobacco-product user groups: never user (never), e-cigarette user (e-cig), SLT user (SLT), and cigarette user (cig) are mutually exclusive.](nihms-1516279-f0001){#F1}

###### 

Definition of tobacco products user groups and specific product user groups for the present study ([@R19]).

  Definition^[a](#TFN1){ref-type="table-fn"}^                                                                              
  ------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***1a: Tobacco user groups***                                                                                            
  Never-tobacco user (never user) (n = 1700)                                                                               Has never used any tobacco products
  Exclusive current established combustible products user (combustible products user) (n = 5767)                           1\. Has ever used at least one of the combustible products: cigarette, traditional cigar, cigarillo, filtered cigar, hookah, and pipe.
                                                                                                                           2\. Has used \> 100 cigarettes in their entire life or fairly regularly used one or more of the following products: cigar, hookah, and pipe.
                                                                                                                           3\. Now use everyday or some days.
                                                                                                                           4\. Not current established users for any non-combustible products (answer "No" for each noncombustible products from questionnaire) (missing will not be included)
  Exclusive current established non-combustible products user (noncombustible products user) (n = 860)                     1\. Has ever used at least one of the non-combustible products: e-cigarette, smokeless tobacco, snus pouches, and dissolvable tobacco.
                                                                                                                           2\. Has used fairly regularly.
                                                                                                                           3\. Now use everyday or some days.
                                                                                                                           4\. Not current established users for any combustible products (answer "No" for each combustible products from questionnaire) (missing will not be included).
  Mixed dual user (dual user) (n = 1258)                                                                                   Users who meet definition 1--3 for both combustible products user and non-combustible products user
  Others (other user) (n = 1934)                                                                                           Users who do not meet the above definitions for never user, combustible products user, noncombustible products user, or dual user
  ***1b: Specific product user group***                                                                                    
  Exclusive current established cigarette user (cigarette user) (n = 3964) (subset of combustible products user)           1\. Includes only cigarettes.
  2\. Has ever used a cigarette                                                                                            
                                                                                                                           3\. Has used \> 100 of the cigarettes in their entire life
                                                                                                                           4\. Now use everyday or some days
                                                                                                                           5\. Currently does not use any other products
  Exclusive current established smokeless users (SLT user) (n = 509) (subset of non-combustible products user)             1\. Includes moist snuff, dip, spit, chewing tobacco, loose snus and pouched snus
  2\. Has ever used a smokeless product                                                                                    
                                                                                                                           3\. Has used fairly regularly
                                                                                                                           4\. Now use everyday or some days
                                                                                                                           5\. Currently does not use any other products
  Exclusive current established e-cigarette users (e-cigarette user) (n = 280) (subset of non-combustible products user)   1\. Has ever used a e-cigarette product
  2\. Has used fairly regularly                                                                                            
                                                                                                                           3\. Now use everyday or some days
                                                                                                                           4\. Currently does not use any other products
  Never-tobacco user (never user) (n = 1700)                                                                               Has never used any tobacco products

To belong to a given user group category, a person must meet all conditions included under the definition ofthe category.

###### 

Geometric mean biomarker concentrations (95% confidence intervals) of different specific tobacco-product user groups by frequency and last time used, PATH Study Wave 1 (2013--2014)^[a](#TFN2){ref-type="table-fn"}^.

  Biomarker                  Specific Product type   Frequency of usage   When last use                                                                                                                                                                                                      
  -------------------------- ----------------------- -------------------- --------------- --------------------------------------------------- ----- --------------------------------------------------- ------ ------------------- ----- --------------------------------------------------- -----
  1-Hydroxynaphthalene       Cigarette               13.2(12.3--14.2)     3223            3.29(2.93--3.69)                                    740   14.2(13.2--15.3)                                    2759   6.22(5.52--7.02)    969   1.69(1.37--2.10)                                    233
                             SLT                     1.42(1.23--1.64)     398             1.46(1.12--1.91)^[†](#TFN3){ref-type="table-fn"}^   111   1.42(1.19--1.7)                                     329    1.38(1.16--1.64)    139   1.69(1.03--2.78)^[†](#TFN3){ref-type="table-fn"}^   40
                             E-cigarette             1.53(1.24--1.90)     187             2.14(1.46--3.14)                                    93    1.39(1.10--1.75)^[†](#TFN3){ref-type="table-fn"}^   156    2.35(1.41--3.92)b   72    1.92(1.20--3.08)^[†](#TFN3){ref-type="table-fn"}^   51
  2-Hydroxynaphthalene       Cigarette               14.5(13.9--15.2)     3221            7.31(6.80--7.86)                                    740   15.0(14.3--15.7)                                    2757   10.2(9.33--11.1)    969   5.23(4.54--6.02)                                    233
                             SLT                     4.6(3.97--5.33)      398             3.75(3.01--4.67)                                    111   4.78(4.02--5.68)                                    329    3.68(3.17--4.26)    139   4.03(2.74--5.92)^[†](#TFN3){ref-type="table-fn"}^   40
                             E-cigarette             4.88(4.15--5.74)     186             7.02(5.01--9.85)                                    93    4.75(4.03--5.59)                                    156    6.83(4.92--9.48)    71    5.91(3.70--9.46)                                    51
  2--Hydroxyfluorene         Cigarette               1147(1098--1199)     3223            382(353--413)                                       740   1224(1167--1283)                                    2760   623(575--674)       968   223(196--253)                                       233
                             SLT                     336(301--375)        398             227(179--287)                                       111   359(313--411)                                       329    235(199--277)       139   222(142--349)^[†](#TFN3){ref-type="table-fn"}^      40
                             E-cigarette             197(167--233)        187             285(203--401)                                       93    192(163--225)                                       156    257(167--397)       72    262(182--376)                                       51
  3-Hydroxyfluorene          Cigarette               665(636--696)        3224            189(172--208)                                       740   707(672--743)                                       2760   355(325--389)       969   91.4(78.4--107)                                     233
                             SLT                     170(152--189)        398             108(83.3--140)                                      111   181(159--207)                                       329    118(97.8--142)      139   96.4(59.0--157)^[†](#TFN3){ref-type="table-fn"}^    40
                             E-cigarette             76.5(63.5--92)       187             118(82.1--170)                                      93    72.5(60--87.7)                                      156    108(69.1--169)      72    108(71.8--163)                                      51
  1-Hydroxyphenanthrene      Cigarette               183(176--190)        3224            127(115--141)                                       740   189(181--197)                                       2760   141(133--149)       969   118(92.1--150)                                      233
                             SLT                     144(124--168)        398             102(83.5--125)                                      111   150(126--180)                                       329    107(89.8--128)      139   109(76.9--155)^[†](#TFN3){ref-type="table-fn"}^     40
                             E-cigarette             102(90.3--116)       187             126(99.2--160)                                      93    99(87.6--112)                                       156    123(92.7--163)      72    121(89.7--164)                                      51
  Σ2,3-Hydroxyphenanthrene   Cigarette               315(301--330)        3224            179(165--194)                                       740   333(319--348)                                       2760   213(199--229)       969   140(117--169)                                       233
                             SLT                     231(205--261)        398             150(123--183)                                       111   242(211--278)                                       329    165(140--194)       139   151(105--218)^[†](#TFN3){ref-type="table-fn"}^      40
                             E-cigarette             118(102--136)        187             158(123--203)                                       93    113(98.1--131)                                      156    153(110--213)       72    146(108--198)                                       51
  1-Hydroxypyrene            Cigarette               333(321--346)        3224            203(188--220)                                       740   344(329--360)                                       2760   247(233--262)       969   170(154--188)                                       233
                             SLT                     180(158--206)        398             140(119--164)                                       111   184(158--214)                                       329    149(132--170)       139   140(103--190)^[†](#TFN3){ref-type="table-fn"}^      40
                             E-cigarette             150(135--166)        187             185(154--224)                                       93    144(128--162)                                       156    188(151--233)       72    171(137--212)                                       51

GM concentration in μg/L for 1-hydroxynaphthalene and 2-hydroxynaphthalene; in ng/L for the rest of the biomarkers.

Estimate should be interpreted with caution because it has low precision. It is based on a denominator sample size of \< 50, or the coefficient of variation of the estimate or its complement is larger than 30% ([@R5]).

[^1]: 1 This article was prepared while Dr. Kevin Conway was employed at the NIH/National Institute on Drug Abuse.
